ClinicalTrials.govpublic full text
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
breast cancer, triple-negative breast cancer, anti-pd-1 antibody, vegfr2 tki, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 839634
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.